No description available.

2009 wurde die deutsche S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit“ publiziert, in der klare Empfehlungen für die Diagnostik, die Indikationen für eine Eradikation, die Therapie und das Follow-Up beschrieben sind. Das Management der H. pylori Infektion im praktischen Alltag zeigt nach dieser Arbeit indessen ein anderes Bild. Ein Optimierungsbedarf für die Zukunft kann daraus abgeleitet werden. Diese Arbeit beschäftigt sich mit dem poststationären Management von Patienten mit einer H. pylori Infektion im Raum Aschaffenburg. Hierzu wurden 199 Patienten identifiziert, bei denen im Rahmen eines stationären Aufenthaltes im Klinikum Aschaffenburg im Jahr 2011 eine H. pylori Infektion diagnostiziert worden war. Aus den Patientenakten wurden alle relevanten Daten entnommen, wie zum Beispiel Diagnose, Indikation zur H. pylori Eradikation und deren stationäre Initiierung beziehungsweise Empfehlung an den Hausarzt. Nachfolgend wurden die 97 Hausärzte der 199 Patienten angeschrieben und um das ausfüllen eines Fragebogens gebeten. Dieser enthielt sechs Fragen zum poststationären Management der Patienten mit H. pylori Infektion. Während des stationären Aufenthaltes war bei 88/199 Patienten (44,2%) die Eradikationstherapie begonnen und bei 24 von ihnen (12,1%) bereits abgeschlossen worden. Bei den anderen 64 Patienten sollte die Medikation ambulant fortgeführt werden. Bei 77 Patienten (38,7%) wurde dem Hausarzt die Einleitung einer ambulanten Eradikationsbehandlung empfohlen. 34 Patienten verließen das Krankenhaus ohne Therapie und auch ohne entsprechende Therapieempfehlung. Die Rücklaufquote der Fragebögen betrug 46,2% (92 von 199 Patienten). Die nachfolgenden Ergebnisse beziehen sich auf diese 92 Patienten (entspricht 100%). Zwei Drittel der Patienten (n=61) stellten sich direkt im Anschluss an die Entlassung aus stationärer Behandlung ihrem Hausarzt vor. Bei 30 Patienten führte der Hausarzt die stationäre begonnene Eradikationstherapie fort (32,6%) oder initiierte sie bei 28 Patienten selbst (30,4%). 17 Patienten erhielten keine Eradikation (18,5%). Die Gründe hierfür waren unterschiedlich, am häufigsten lag ein Informationsdefizit zwischen Klinik und Hausarzt vor. Die französische Triple-Therapie wurde mit 39 mal am häufigsten verordnet, die italienische Triple-Therapie wurde 20 Patienten verschrieben. Andere Behandlungsprotokolle fanden nur vereinzelt Anwendung. Eine Kontrolle des Eradikationserfolges wurde bei 35 Patienten (38%) vorgenommen. Bezieht man die Eradikationskontrolle ausschließlich auf die therapierten Patienten erfolgte diese in der Hälfte der Fälle (49,3%). Von den Patienten mit H. pylori Eradikation und Kontrolle des Eradikationserfolges (n=35) konnten 31 (88,6%) erfolgreich behandelt werden. Die Vorgehensweise nach erfolgloser H. pylori Eradikation umfasste den Versuch einer Zweitlinientherapie, die Überweisung zum Gastroenterologen und den Verzicht auf weitere Maßnahmen. Zusammenfassend zeigt diese Erhebung, dass es einen klaren Optimierungsbedarf in der Anwendung der Empfehlungen aus der Leitlinie bedarf. Dieser Aspekt sollte zukünftig vermehrt Berücksichtigung finden, nicht zuletzt in der Aktualisierung der Leitlinie 2016. / In 2009, the German S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease" was published, in which clear recommendations for diagnosis, the indications for eradication, therapy and follow-up are described. However, the management of H. pylori infection in everyday practice shows a different picture. An optimization requirement for the future can be derived from this. This thesis deals with post-hospital management of patients with H. pylori infection in the area of Aschaffenburg. 199 patients were identified who had been diagnosed with H. pylori infection during their inpatient stay at Aschaffenburg Hospital in 2011. All relevant data were taken from the patient records, such as diagnosis, indication for H. pylori eradication and their inpatient therapy initiation or recommendation to the family doctor. Subsequently, the 97 general practitioners of the 199 patients were contacted and asked to complete a questionnaire. This included six questions about post-hospital management of patients with H. pylori infection. During inpatient treatment, eradication therapy had started in 88/199 patients (44.2%) and had already been completed in 24 of them (12.1%). For the other 64 patients, the medication should be continued on an outpatient basis. In 77 patients (38.7%) the family doctor received a recommended to initiate an eradication therapy. Thirty-four patients left the hospital without therapy and without appropriate therapy recommendation. The response rate of the questionnaires was 46.2% (92 out of 199 patients). The following results refer to these 92 patients (equivalent to 100%). Two-thirds of the patients (n = 61) presented themselves to their family doctor immediately after discharge from hospitalization. In 30 patients, the family doctor continued inpatient eradication therapy (32.6%) or initiated it in 28 patients (30.4%). 17 patients received no eradication (18.5%). The reasons for this varied, with the most common being an information deficit between the clinic and the family doctor. The French triple therapy was prescribed most often in 39 times, the Italian triple therapy was prescribed to 20 patients. Other treatment protocols were used only sporadically. A control of eradication success was made in 35 patients (38%). If the eradication control was exclusively applied to the treated patients, this was done in half of the cases (49.3%). Of the patients with H. pylori eradication and control of eradication success (n = 35), 31 (88.6%) were successfully treated. The procedure after unsuccessful H. pylori eradication included the attempt of a second-line therapy, the referral to the gastroenterologist and the renunciation of further steps. In summary, this scientific work shows that there is a clear need for optimization in the application of the Guideline recommendations. This aspect should be taken more into account in the future, not least in the update of the upcoming guideline update 2016.

Helicobacter pylori infection causes chronic type B gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tumor. Infection with H. pylori is common in parts of the developing world. The Clínica Misional Nuestra Señora de Guadalupe serves indigenous people of the Ecuadorian Amazon. At the clinic, gastritis is a common diagnosis that is based solely on reported symptoms and is presumed to be due to H. pylori infection. Additionally, gastric cancer, a corollary of H. pylori infection, is the leading cause of cancer deaths in Ecuador and, thus, an important public health concern. To the best of our knowledge, the prevalence of H. pylori infection among the inhabitants of rural Ecuador has never been assessed. The primary aim of this study was to determine the seroprevalence of H. pylori in this population. We compared rates of seropositivity among patients with and without symptoms suggestive of gastritis and among patients who reported untreated and exclusively treated water consumption. Additionally, a sampling of children was tested to begin to assess the age of serological conversion. Using the Quidel QuickVue H. pylori gII test, we found near universal seropositivity among adults aged 18 to 65 years (117/120 = 98%) and among children aged 2 to 18 years (13/14 = 93%). Given the high prevalence of H. pylori and its complications in rural Ecuador, this population may benefit from intervention to eradicate the bacterium. However, there is a lack of evidence to inform management decisions. There is a need for studies with large numbers of patients and long-term follow-up to assess the costs and benefits of population-based treatment.

published_or_final_version / Public Health / Master / Master of Public Health

published_or_final_version / abstract / toc / Medicine / Master / Doctor of Medicine

Helicobacter pylori infects more than half of the world's population, and is known to be involved in several diseases including gastric cancer. Its close interactions with the stomach and host immune system serves as a good model to study the co-adaptation and co-evolution of the organisms in the stomach micro-environment. In this project, we utilized RNA-seq and data analysis tools to investigate differentially expressed genes by H. pylori in patients at different stages of early gastric cancer development. We also investigated the abundance and diversity of bacterial genera other than H. pylori, and looked for correlations with H. pylori presence and number. For differential gene expression of H. pylori, one gene was differentially expressed between samples of corpus atrophy without metaplasia vs. samples of antrum gastritis, and eight genes were found to be differentially expressed between samples of corpus atrophy with metaplasia vs. samples with pan-gastritis. When samples were clustered into different groups based on the expression data, 52 genes (shared or unique to the specific comparison groups) were found to be differentially expressed, but no apparent patterns were observed that could be explained by medical or sample collection data. For bacterial diversity and abundances, we found several genera colonizing the stomach, of which some have been previously identified. While most of these bacteria colonize regardless of the presence of H. pylori, the abundance of three genera, Wolinella, Campylobacter, and Veillonella, seem to be correlated with the presence of H. pylori.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2007. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.